CN114853667A - 一种手性吡哆醛催化剂及其制备方法与应用 - Google Patents
一种手性吡哆醛催化剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN114853667A CN114853667A CN202210459627.8A CN202210459627A CN114853667A CN 114853667 A CN114853667 A CN 114853667A CN 202210459627 A CN202210459627 A CN 202210459627A CN 114853667 A CN114853667 A CN 114853667A
- Authority
- CN
- China
- Prior art keywords
- pyridoxal
- formula
- acid
- catalyst
- chiral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 title claims abstract description 168
- 229960003581 pyridoxal Drugs 0.000 title claims abstract description 87
- 235000008164 pyridoxal Nutrition 0.000 title claims abstract description 87
- 239000011674 pyridoxal Substances 0.000 title claims abstract description 87
- 239000003054 catalyst Substances 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000002253 acid Substances 0.000 claims abstract description 20
- -1 amino alcohol compound Chemical class 0.000 claims abstract description 15
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000007294 asymmetric addition reaction Methods 0.000 claims abstract description 10
- 230000009471 action Effects 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 238000006482 condensation reaction Methods 0.000 claims abstract description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 claims description 8
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 8
- 150000002430 hydrocarbons Chemical group 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 6
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229940043279 diisopropylamine Drugs 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- 239000011698 potassium fluoride Substances 0.000 claims description 4
- 235000003270 potassium fluoride Nutrition 0.000 claims description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 4
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 4
- WLAWBAYUZCKKJS-UHFFFAOYSA-N 1-cyclododecyl-1,2-diazacyclododecane Chemical compound N1(NCCCCCCCCCC1)C1CCCCCCCCCCC1 WLAWBAYUZCKKJS-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- 239000012317 TBTU Substances 0.000 claims description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940071870 hydroiodic acid Drugs 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FLUVVESHOANMOG-UHFFFAOYSA-N 1-cyclodecyldiazecane Chemical compound C1CCCCCCCCC1N1NCCCCCCCC1 FLUVVESHOANMOG-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 238000007306 functionalization reaction Methods 0.000 abstract description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 238000005481 NMR spectroscopy Methods 0.000 description 129
- 239000012043 crude product Substances 0.000 description 68
- 239000007787 solid Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 38
- 238000004440 column chromatography Methods 0.000 description 37
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 34
- 238000004128 high performance liquid chromatography Methods 0.000 description 34
- 238000007036 catalytic synthesis reaction Methods 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- ASQOQJYHIYYTEJ-GBESFXJTSA-N (1r,7s,9as)-7-decyl-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-ol Chemical compound O[C@@H]1CCCN2C[C@@H](CCCCCCCCCC)CC[C@H]21 ASQOQJYHIYYTEJ-GBESFXJTSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 125000002050 pyridoxal group Chemical group 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- FYGHSUNMUKGBRK-UHFFFAOYSA-N 1,2,3-trimethylbenzene Chemical compound CC1=CC=CC(C)=C1C FYGHSUNMUKGBRK-UHFFFAOYSA-N 0.000 description 4
- BPQRHXHHIOBCJI-UHFFFAOYSA-N CC1N(C)C=C(CO)C(C=O)=C1O Chemical class CC1N(C)C=C(CO)C(C=O)=C1O BPQRHXHHIOBCJI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000003592 biomimetic effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000004705 aldimines Chemical class 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 1
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical group CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 1
- LIDUGWDLSDKCLM-CSKARUKUSA-N 4-[[3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C#N)=C1 LIDUGWDLSDKCLM-CSKARUKUSA-N 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 238000010499 C–H functionalization reaction Methods 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125880 compound 4j Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0245—Nitrogen containing compounds being derivatives of carboxylic or carbonic acids
- B01J31/0247—Imides, amides or imidates (R-C=NR(OR))
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
- B01J2231/34—Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
- B01J2231/341—1,2-additions, e.g. aldol or Knoevenagel condensations
- B01J2231/342—Aldol type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues, to aldehydes or ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域
本发明属于有机催化技术领域,涉及一种手性吡哆醛催化剂及其制备方法与应用,尤其涉及一种新型手性吡哆醛催化剂与合成方法及其在炔丙胺α位C-H键官能团化反应中的应用。
背景技术
在生物体内,酶催化甘氨酸对醛的直接加成生成β-羟基-α-氨基酸的反应,化学家们已有广泛的认识,该过程条件温和,甘氨酸直接参与反应,不需要任何保护基。该反应中,酶的活性中心是维生素B6,在体内以磷酸吡哆醛和磷酸吡哆胺的形式存在(PMP和PLP)。但酶催化过程同时也面临着价格昂贵、易失活等局限,因此开发相应的仿生催化过程具有重要意义。Kuzuhara和Breslow课题组利用化学计量的手性吡哆醛模拟生物体内酶催化甘氨酸对醛的加成反应,做出了很多开创性的工作[H.Kuzuhara,N.Watanabe,M.Ando,J.Chem.Soc.,Chem.Commun.1987,95-96;M.Ando,H.Kuzuhara,Bull.Chem.Soc.Jpn.1990,63,1925-1928;J.T.Koh,L.Delaude,R.Breslow,J.Am.Chem.Soc.1994,116,11234-11240]。但是,这些反应只能得到中等的对映选择性和较差的非对映选择性。
基于前人对手性吡哆醛的研究,赵宝国课题组发展了多种新型高效的手性N-甲基吡哆醛类化合物,已成功应用于甘氨酸衍生物与亚胺或酮的仿生不对称Mannich反应和aldol反应,分别合成了具有高立体选择性的手性α,β-二氨基酯和β-羟基-α-氨基酸酯[J.Chen,X.Gong,J.Li,Y.Li,J.Ma,C.Hou,G.Zhao,W.Yuan,B.Zhao,Science 2018,360,1438-1442;A.Cheng,L.Zhang,Q.Zhou,T.Liu,J.Cao,G.Zhao,K.Zhang,G.Song,B.Zhao,Angew.Chem.Int.Ed.2021,60,20166-20172]。在以上催化过程中,催化剂均为N-甲基吡哆醛类化合物,亲核试剂均为活性较高的甘氨酸,即N-甲基吡哆醛只实现了高活性甘氨酸α位C-H键官能团化。而对于其他活性较低的伯胺如炔丙胺α位C-H键官能团化,利用现有的N-甲基吡哆醛则难以实现。因此,开发一种新型高效的手性吡哆醛类化合物,催化实现弱活化伯胺如炔丙胺α位C-H键官能团化,并应用于炔丙胺对三氟甲基酮的加成,合成手性β-胺基-α-三氟甲基醇衍生物,有着重要的理论意义和很好的应用潜力。
发明内容
本发明的目的就是提供一种新型手性吡哆醛催化剂与合成方法及其在炔丙胺α位C-H键官能团化反应中的应用,用于实现弱活化炔丙胺α位C-H键官能团化,并应用于催化炔丙胺对三氟甲基酮的不对称加成反应,合成一系列具有高立体选择性的β-胺基-α-三氟甲基醇衍生物。
本发明的目的可以通过以下技术方案来实现:
一种吡哆醛催化剂,具有如式1所示的结构式:
进一步包括如式(R,S)-1、式(S,R)-1、式(S,R)-1所示的手性化合物:
式中,R1为C1-24的烃基或羟甲基;R2、R3分别为氢或C1-24的烃基。
进一步地,R1为羟甲基、甲基、乙基、正丙基、异丙基、正丁基、环戊基、环己基、环庚基、苯基、苄基、(1-苯基)乙基、1-萘基、2-萘基或卤素中的一种;
R2、R3分别为氢、甲基、乙基、正丙基、异丙基、正丁基、叔丁基、环戊基、环己基、环庚基、苯基、苄基、2-联苯基、3-联苯基、4-联苯基、2,6-二联苯基、3,5-二联苯基、1-萘基或2-萘基中的一种。
一种手性吡哆醛催化剂的制备方法,包括:
将式5所示的手性酸化合物与式6所示的氨基醇化合物在缩合剂与碱的作用下进行缩合反应,得到式7所示的化合物;再将式7所示的化合物在酸的作用下水解,即得到如式1所示的手性吡哆醛催化剂。
其中式5所示的手性酸化合物按照文献方法制备[J.Chen,X.Gong,J.Li,Y.Li,J.Ma,C.Hou,G.Zhao,W.Yuan,B.Zhao,Science 2018,360,1438-1442],式5所示的手性酸化合物的轴手性构型与式1所示的吡哆醛催化剂的轴手性构型保持一致。
进一步地,所述的缩合反应中,手性酸化合物与氨基醇化合物的摩尔比为1:(1-5),反应温度为0-100℃,反应时间为1-48h。
进一步地,所述的缩合剂包括EDCl、DCC、DIC、HATU、HBTU、HCTU、TBTU、TSTU、TNTU、HOAt、HOBt中的至少一种,手性酸化合物与缩合剂的摩尔比为1:(1-10),缩合剂的作用为促进手性酸化合物形成活性酯或活性酰胺。
所述的碱包括氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾、氢化钙、氟化钾、三乙胺、二异丙胺、二异丙基乙基胺、四甲基乙二胺、N,N-二甲基苯胺、N,N-二乙基苯胺、1,4-二氮杂二环辛烷(DABCO)、二氮杂二环十二烷(DBU)、正丁基锂、1,4-二甲基哌嗪、1-甲基哌啶、1-甲基吡咯、喹啉或吡啶中的至少一种,手性酸化合物与碱的摩尔比为1:(1-10)。
进一步地,水解过程中,式7所示的化合物与酸的摩尔比为1:(1-50),反应温度为0-100℃,反应时间为1-48h。
进一步地,所述的酸包括硫酸、盐酸、磷酸、氢溴酸、氢碘酸、醋酸、三氟乙酸、三氯乙酸、苯磺酸、对甲苯磺酸、甲磺酸或三氟甲磺酸中的至少一种,酸溶液的溶剂包括水、二氯甲烷、甲醇、四氢呋喃或二氧六环中的一种。
作为优选的技术方案,手性吡哆醛催化剂的制备过程中,所用溶剂包括水、苯、甲苯、二甲苯、三甲苯、乙腈、乙醚、四氢呋喃(THF)、乙二醇二甲醚、氯仿、二氯甲烷(DCM)、甲醇、乙醇、异丙醇、叔丁醇、1,4-二氧六环、N,N–二甲基甲酰胺、N,N–二甲基乙酰胺、二甲基亚砜或N-甲基吡咯烷酮中的至少一种。
一种手性吡哆醛催化剂的应用,包括将所述的手性吡哆醛催化剂用于三氟甲基酮的不对称加成反应,具体包括:
将式2所示的炔丙胺、式3所示的三氟甲基酮混合,并在手性吡哆醛催化剂与碱的作用下进行不对称加成反应,得到手性β-胺基-α-三氟甲基醇,即式(3R,4S)-4所示的化合物或式(3S,4S)-4所示的化合物;其中,当手性吡哆醛催化剂轴手性构型为S时,得到的产物为式(3R,4S)-4所示的化合物;当手性吡哆醛催化剂轴手性构型为R时,得到的产物为式(3S,4S)-4所示的化合物;
式中,R4、R5分别为氢、下述基团或者含有取代基的下述基团:C1~C24的烃基、C3~C30的环烷基或芳基、C1~C24的羰基、C1~C24的磺酰基或磷酰基;
所述的取代基包括卤素、C1~C8的烃基、C3~C12的环烷基或芳基、C1~C8的羰基、C1~C8的磺酰基或磷酰基、C1~C8的烷氧基或胺基中的至少一种;
其中,所述的羰基为醛基、酮羰基、酯羰基、羧基或酰胺基。
进一步地,所述的不对称加成反应中,式2所示的炔丙胺、式3所示的三氟甲基酮、手性吡哆醛催化剂的摩尔比为(0.5-5):1:(0.01-0.5),式2所示的炔丙胺与碱的摩尔比为1:(1-20),反应温度为-10℃至100℃,反应时间为1-72h。
进一步地,所述的碱包括氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾、氢化钙、氟化钾、三乙胺、二异丙胺、二异丙基乙基胺、四甲基乙二胺、N,N-二甲基苯胺、N,N-二乙基苯胺、1,4-二氮杂二环辛烷(DABCO)、二氮杂二环十二烷(DBU)、正丁基锂、1,4-二甲基哌嗪、1-甲基哌啶、1-甲基吡咯、喹啉或吡啶中的至少一种。
作为优选的技术方案,所述的不对称加成反应中,所用溶剂包括水、甲醇、乙醇、异丙醇、正丙醇、正丁醇、三氟乙醇、苯、甲苯、二甲苯、三甲苯、乙腈、乙醚、四氢呋喃、乙二醇二甲醚、氯仿、二氯甲烷、N,N-二甲基甲酰胺、N,N–二甲基乙酰胺、二甲基亚砜或N-甲基吡咯烷酮中的至少一种。
与现有技术相比,本发明具有以下特点:
1)吡哆醛是一类非常重要的、具有很好生物活性的化合物,在生物体系中,它是许多生物酶的辅酶,可以催化甘氨酸衍生物对醛的加成,合成α-羟基-β-氨基酸衍生物。本发明通过模拟生物体内的酶催化过程,开发了一系列手性吡哆醛催化剂,成功实现了弱活化炔丙胺α位C-H键官能团化,并将其应用于炔丙胺对三氟甲基酮的不对称加成反应,实现具有光学活性的手性β-胺基-α-三氟甲基醇衍生物的快捷、有效合成;
2)本发明中的手性吡哆醛催化剂可以由廉价易得的原料经多步反应制得,反应条件温和,大多易于放大,可以较大规模制备;
3)本发明中吡哆醛催化剂催化的仿生不对称加成反应是制备手性β-胺基-α-三氟甲基醇酸衍生物的一种新方法,该方法模拟了生物体内的酶催化过程:手性吡哆醛催化剂与炔丙胺缩合形成醛亚胺,该醛亚胺的α位C-H去质子化后得到一个活性的碳负离子中间体,然后对三氟甲基酮进行加成,经过水解,生成β-胺基-α-三氟甲基醇,并且重新生成手性吡哆醛催化剂,完成该催化循环过程;
4)本发明中吡哆醛催化剂催化该反应条件非常温和,对水和空气都不很敏感,可以在水中进行,反应稳定,容易操作,产物选择性,具有极高的dr值和ee值,收率较高,是制备手性β-胺基-α-三氟甲基醇衍生物的一种有效方法,因此本发明具有较好的应用价值。
具体实施方式
下面结合具体实施例对本发明进行详细说明。本实施例以本发明技术方案为前提进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
实施例1:化合物(S)-7的合成
将化合物(S)-5(0.20g,0.47mmol)、化合物6(0.107g,1.17mmol)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCl,0.135g,0.705mmol)、1-羟基苯并三唑(HOBt,0.095g,0.705mmol)溶于新蒸的DCM(3.0mL)中,再注入Et3N(0.143g,1.41mmol)。室温下搅拌15小时后,加入3mL水淬灭反应。随后,所得产物混合物用DCM萃取(5mL×3),合并有机相,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩滤液,柱层析得到化合物(S)-7(白色固体,0.193g,产率82%)。
White solid;M.p.114-115℃;[α]D 25=98.3(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.51(s,1H),7.93(d,J=8.4Hz,1H),7.88(d,J=8.0Hz,1H),7.80(d,J=8.4Hz,1H),7.51(t,J=7.4Hz,1H),7.37(t,J=8.0Hz,1H),7.33(d,J=8.0Hz,1H),7.24(d,J=8.4Hz,1H),5.35(d,J=6.8Hz,1H),5.24(d,J=7.2Hz,1H),5.21(s,1H),3.90-3.82(m,1H),3.62(d,J=4.8Hz,2H),3.57(s,3H),3.46-3.41(m,2H),3.26(q,J=6.8Hz,2H),3.14-3.02(m,H),2.01(s,3H),0.96(t,J=7.0Hz,3H),0.69(t,J=7.0Hz,1H);13C NMR(100MHz,CDCl3)δ169.4,151.9,149.6,139.1,135.5,134.00,133.97,132.3,132.1,131.4,128.8,128.3,127.1,126.7,126.6,125.8,99.4,96.4,64.8,64.2,62.8,62.6,56.6,53.0,22.3,14.9,14.3;HRMS m/z Calcd.for C27H35N2O7(M+H)+:499.2439;Found:499.2440.
其中例1式5所示的手性酸化合物按照文献方法制备[J.Chen,X.Gong,J.Li,Y.Li,J.Ma,C.Hou,G.Zhao,W.Yuan,B.Zhao,Science 2018,360,1438-1442]。
实施例2:化合物(S)-1的合成
将实施例1制备的化合物(S)-7(0.193g,0.387mmol)溶于THF(2.0mL)中,随后注入1M盐酸水溶液(2.0mL),50℃下搅拌11小时后,加入饱和碳酸氢钠水溶液中和pH至7,旋去溶剂,柱层析得到化合物(S)-1(黄色固体,0.085g,产率58%)。
Yellow solid;M.p.90-93℃;[α]D 25=40.0(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ10.86(brs,1H),9.36(s,1H),8.49(s,1H),8.01(d,J=8.8Hz,1H),7.97(d,J=8.0Hz,1H),7.70(d,J=8.4Hz,1H),7.60(t,J=7.6Hz,1H),7.50(t,J=7.8Hz,1H),7.25(d,J=8.0Hz,1H),6.64(d,J=8.0Hz,1H),3.88(brs,1H),3.79(d,J=11.2Hz,1H),3.60(t,J=10.4Hz,2H),3.40-3.34(m,1H),2.07(s,3H);13C NMR(100MHz,CDCl3)δ197.4,169.0,153.3,148.2,141.4,134.5,134.0,132.6,131.9,130.0,129.8,128.8,128.4,127.9,126.0,123.71,123.66,62.8,62.6,52.0,21.3;HRMS m/z Calcd.for C21H21N2O5(M+H+):381.1445;Found:381.1445.
实施例3:手性吡哆醛类催化剂(R,S)-1a催化合成β-胺基-α-三氟甲基醇4a
依次将手性吡哆醛催化剂(S)-1a(4.3mg,0.01mmol)、K2CO3(41.5mg,0.30mmol)加入到2mL反应瓶中,注入DCM(0.3mL),再依次注入炔丙胺2a(41.5mg,0.3mmol)、三氟酮3a(50.4mg,0.20mmol)、H2O(20μL),加入搅拌子,盖上塞子,25℃下搅拌36小时。之后加入一水合肼溶液(20μL,80wt%in H2O)搅拌30min淬灭反应,旋去溶剂,柱层析得到化合物4a(黄色固体,37.8mg,产率49%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-94%。
Yellow solid;M.p.67-70℃;[α]D 25=27.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.12(d,J=8.4Hz,1H),7.84(d,J=8.4Hz,1H),7.75-7.70(m,1H),7.46-7.28(m,9H),4.26(s,1H),3.50-3.34(m,1H),3.33-3.21(m,1H),2.42-2.27(m,2H);13C NMR(100MHz,CDCl3)δ138.1,134.0,131.9,131.8,128.92,128.90,128.5,127.1,126.34(q,JC-F=285.4Hz),126.33,126.2,125.8,125.7,123.8,122.2,86.9,85.9,75.1(q,JC-F=25.8Hz),46.3,34.3,28.2,26.7;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/z Calcd.for C23H21F3NO(M+H+):384.1570;Found:384.1574.
实施例4:手性吡哆醛类催化剂(R,S)-1b催化合成β-胺基-α-三氟甲基醇4a
与实施例3相比,区别仅在于:采用吡哆醛(R,S)-1b取代(R,S)-1a,其余同实施例3。柱层析得到化合物4a(黄色固体,34.5mg,产率45%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-94%。
实施例5:手性吡哆醛类催化剂(R,S)-1c催化合成β-胺基-α-三氟甲基醇4a
与实施例3相比,区别仅在于:采用吡哆醛(R,S)-1c取代(R,S)-1a,其余同实施例3。柱层析得到化合物4a(黄色固体,30.5mg,产率45%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-93%。
实施例6:手性吡哆醛类催化剂(R,S)-1d催化合成β-胺基-α-三氟甲基醇4a
与实施例3相比,区别仅在于:采用吡哆醛(R,S)-1d取代(R,S)-1a,其余同实施例3。柱层析得到化合物4a(黄色固体,34.8mg,产率44%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为10:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-91%。
实施例7:手性吡哆醛类催化剂(R,S)-1e催化合成β-胺基-α-三氟甲基醇4a
与实施例3相比,区别仅在于:采用吡哆醛(R,S)-1e取代(R,S)-1a,其余同实施例3。柱层析得到化合物4a(黄色固体,11.9mg,产率15%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为1.8:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-88%。
实施例8:手性吡哆醛类催化剂(R,S)-1f催化合成β-胺基-α-三氟甲基醇4a
与实施例3相比,区别仅在于:采用吡哆醛(R,S)-1f取代(R,S)-1a,其余同实施例3。柱层析得到化合物4a(黄色固体,10.3mg,产率13%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为1.3:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为-88%。
实施例9:手性吡哆醛类催化剂(R,S)-1g催化合成β-胺基-α-三氟甲基醇4a
依次将手性吡哆醛催化剂(S)-1g(7.6mg,0.02mmol)、K2CO3(41.5mg,0.30mmol)加入到2mL反应瓶中,注入DCM(0.3mL),再依次注入炔丙胺2a(41.5mg,0.3mmol)、三氟酮3a(50.4mg,0.20mmol)、H2O(20μL),加入搅拌子,盖上塞子,25℃下搅拌36小时。之后加入一水合肼溶液(20μL,80wt%in H2O)搅拌30min淬灭反应,旋去溶剂,柱层析得到化合物4a(黄色固体,62.2mg,产率81%)。
4a的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4a的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为95%。
Yellow solid;M.p.67-70℃;[α]D 25=27.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.12(d,J=8.4Hz,1H),7.84(d,J=8.4Hz,1H),7.75-7.70(m,1H),7.46-7.28(m,9H),4.26(s,1H),3.50-3.34(m,1H),3.33-3.21(m,1H),2.42-2.27(m,2H);13C NMR(100MHz,CDCl3)δ138.1,134.0,131.9,131.8,128.92,128.90,128.5,127.1,126.34(q,JC-F=285.4Hz),126.33,126.2,125.8,125.7,123.8,122.2,86.9,85.9,75.1(q,JC-F=25.8Hz),46.3,34.3,28.2,26.7;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/z Calcd.for C23H21F3NO(M+H+):384.1570;Found:384.1574.
实施例10:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4b
与实施例9相比,区别仅在于:采用三氟酮3b取代3a,其余同实施例3。柱层析得到化合物4b(黄色油状液体,56.0mg,产率77%)。
4b的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4b的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为95%。
Yellow oil;[α]D 25=25.4(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.42(d,J=6.8Hz,2H),7.37-7.30(m,3H),7.14(d,J=8.0Hz,2H),6.82(d,J=8.0Hz,2H),4.21(s,1H),3.78(s,3H),2.87-2.74(m,2H),2.32-2.10(m,2H);13C NMR(100MHz,CDCl3)δ158.0,133.9,131.8,129.4,128.9,128.5,126.3(q,JC-F=285.5Hz),122.2,114.0,86.7,85.7,74.9(q,JC-F=25.8Hz),55.4,46.2,35.3,28.5;19F NMR(376MHz,CDCl3)δ-76.6;HRMS m/zCalcd.for C20H21F3NO2(M+H+):364.1519;Found:364.1521.
实施例11:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4c
与实施例9相比,区别仅在于:采用三氟酮3c取代3a,其余同实施例3。柱层析得到化合物4c(黄色固体,50.8mg,产率70%)。
4c的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4c的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.85-89℃;[α]D 25=12.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.43(d,J=6.8Hz,2H),7.40-7.29(m,3H),7.12(q,J=7.6Hz,4H),4.22(s,1H),2.94-2.79(m,2H),2.33(s,3H),2.31-2.14(m,2H);13C NMR(100MHz,CDCl3)δ138.8,135.7,131.8,129.3,128.9,128.5,128.4,126.3(q,JC-F=285.4Hz),122.2,86.7,85.7,74.9(q,JC-F=25.7Hz),46.2,35.2,28.9,21.1;19F NMR(376MHz,CDCl3)δ-76.6;HRMS m/zCalcd.for C21H21N2O4(M+H+):365.1501;Found:365.1505.
实施例12:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4d
与实施例9相比,区别仅在于:采用三氟酮3d取代3a,其余同实施例3。柱层析得到化合物4d(白色固体,50.4mg,产率74%)。
4d的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4d的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为93%。
White solid;M.p.65-69℃;[α]D 25=17.5(c=0.1,CHCl3);1H NMR(400MHz,
CDCl3)δ7.44-7.39(m,2H),7.37-7.30(m,3H),7.22(s,1H),7.18(t,J=7.6Hz,2H),7.10(d,J=6.8Hz,1H),4.22(s,1H),2.86(pd,J=12.0,5.6Hz,2H),2.31-2.11(m,2H);13C NMR(100MHz,CDCl3)δ144.0,134.4,131.8,129.9,129.0,128.7,128.6,126.7,126.4,126.3(q,JC-F=285.5Hz),122.1,86.5,86.0,74.7(q,JC-F=25.8Hz),46.2,34.8,29.2.;19FNMR(376MHz,CDCl3)δ-76.7;HRMS m/z Calcd.for C19H18ClF3NO(M+H+):368.1024Found:368.1024.
实施例13:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4e
与实施例9相比,区别仅在于:采用三氟酮3e取代3a,其余同实施例3。柱层析得到化合物4e(黄色固体,65.3mg,产率80%)。
4e的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4e的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.59-62℃;[α]D 25=42.2(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ7.39(d,J=7.4Hz,4H),7.35(d,J=8.0Hz,4H),7.33-7.23(m,5H),7.19(t,J=7.4Hz,2H),4.52(t,J=6.8Hz,1H),4.06(s,1H),2.95(dd,J=15.2,8.0Hz,1H),2.79(dd,J=15.2,5.6Hz,1H);13C NMR(100MHz,CDCl3)δ145.2,145..0,131.8,128.8,128.7,128.5,128.1,127.8,126.6,126.4,126.2(q,JC-F=285.6Hz),122.3,87.1,86.1,76.0(q,JC-F=25.4Hz),47.0,46.0,36.9;19F NMR(376MHz,CDCl3)δ-76.8;HRMS m/z Calcd.for C25H23F3NO(M+H+):410.1726;Found:410.1728.
实施例14:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4f
与实施例9相比,区别仅在于:采用三氟酮3f取代3a,其余同实施例3。柱层析得到化合物4f(黄色油状液体,58.4mg,产率84%)。
4f的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4f的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow oil;[α]D 25=1.6(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ7.39-7.30(m,5H),7.24(d,J=7.6Hz,1H),7.20-7.14(m,3H),4.15(s,1H),2.67(t,J=7.6Hz,2H),2.02-1.95(m,2H),1.94-1.84(m,2H);13C NMR(100MHz,CDCl3)δ141.9,131.8,128.8,128.54,128.51,128.49,126.3(q,JC-F=285.7Hz),126.0,122.2,86.6,85.6,74.9(q,JC-F=25.7Hz),46.2,36.6,32.7,24.7;19F NMR(376MHz,CDCl3)δ-76.7;HRMS m/z Calcd.forC20H21F3NO(M+H+):348.1570;Found:348.1571.
实施例15:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4g
与实施例9相比,区别仅在于:采用三氟酮3g取代3a,其余同实施例3。柱层析得到化合物4g(黄色固体,74.1mg,产率79%)。
4g的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4g的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Yellow solid;M.p.95-100℃;[α]D 25=91.3(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.21(d,J=9.2Hz,1H),8.16(d,J=7.6Hz,1H),8.12(d,J=7.6Hz,1H),8.06(d,J=7.6Hz,1H),8.03-7.96(m,3H),7.95(d,J=9.6Hz,1H),7.87(d,J=8.0Hz,1H),7.29(t,J=7.2Hz,1H),7.20(d,J=7.2Hz,2H),7.17(t,J=7.6Hz,2H),4.14(s,1H),3.39(t,J=6.8Hz,2H),2.24-2.10(m,4H);13C NMR(100MHz,CDCl3)δ136.1,131.6,131.5,131.0,130.0,128.7,128.4,127.6,127.4,126.7,125.9,125.2,125.1,125.0,124.9,124.8,123.4,122.0,86.5,85.6,74.8(q,JC-F=25.6Hz),46.0,34.2,33.2,25.1;19F NMR(376MHz,CDCl3)δ-76.9;HRMSm/z Calcd.for C30H25F3NO(M+H+):472.1883;Found:472.1896.
实施例16:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4h
与实施例9相比,区别仅在于:采用三氟酮3h取代3a,其余同实施例3。柱层析得到化合物4h(黄色固体,43.8mg,产率65%)。
4h的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4h的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Yellow solid;M.p.41-43℃;[α]D 25=28.9(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.42(d,J=7.2Hz,2H),7.36-7.29(m,3H),7.12(d,J=5.2Hz,1H),6.92(t,J=4.4Hz,1H),6.84(s,1H),4.20(s,1H),3.13(qt,J=13.0,5.2Hz,2H),2.38(td,J=13.4,5.6Hz,1H),2.28(td,J=13.4,5.6Hz,1H);13C NMR(100MHz,CDCl3)δ144.6,131.8,128.9,128.5,127.0,126.2(q,JC-F=285.4Hz),124.4,123.4,122.1,86.4,86.0,74.7(q,JC-F=25.8Hz),46.2,35.1,23.7;19F NMR(376MHz,CDCl3)δ-76.7;HRMS m/z Calcd.forC17H17F3NOS(M+H+):340.0977;Found:340.0976.
实施例17:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4i
与实施例9相比,区别仅在于:采用三氟酮3i取代3a,其余同实施例3。柱层析得到化合物4i(淡黄色固体,53.6mg,产率79%)。
4i的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4i的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Pale yellow solid;M.p.59-63℃;[α]D 25=14.3(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.47-7.37(m,2H),7.37-7.28(m,3H),4.16(s,1H),1.99-1.90(m,2H),1.77-1.59(m,5H),1.45-1.36(m,2H),1.27-1.09(m,4H),0.91(q,J=12.0Hz,2H);13C NMR(100MHz,CDCl3)δ131.7,128.8,128.5,126.4(q,JC-F=285.6Hz),122.4,86.9,85.4,75.1(q,JC-F=25.4Hz),,46.22,46.20,38.5,33.4,33.3,30.6,30.1,26.7,26.4;19F NMR(376MHz,CDCl3)δ-76.6;HRMS m/z Calcd.for C19H25F3NO(M+H+):340.1883;Found:340.1885.
实施例18:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4j
与实施例9相比,区别仅在于:采用三氟酮3j取代3a,其余同实施例3。柱层析得到化合物4j(淡黄色固体,62.2mg,产率78%)。
4j的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4j的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Pale yellow solid;M.p.50-53℃;[α]D 25=6.9(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.42(d,J=6.8Hz,2H),7.33(d,J=6.2Hz,2H),4.16(s,1H),1.934(t,J=8.0Hz,2H),1.60-1.48(m,2H),1.36-1.20(m,18H),0.89(t,J=6.4Hz,2H);13C NMR(100MHz,CDCl3)δ131.8,128.8,128.5,126.4(q,JC-F=285.6Hz),122.4,86.8,85.4,75.0(q,JC-F=25.6Hz),46.2,33.1,32.1,30.5,29.78,29.76,29.7,29.5,29.5,22.8,14.2;19F NMR(376MHz,CDCl3)δ-76.6;HRMS m/z Calcd.for C23H35F3NO(M+H+):398.2665;Found:398.2664.
实施例19:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4k
与实施例9相比,区别仅在于:采用三氟酮3k取代3a,其余同实施例3。柱层析得到化合物4k(黄色油状液体,83.4mg,产率74%)。
4k的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4k的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为95%。
Yellow oil;[α]D 25=10.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.69(d,J=7.2Hz,4H),7.46-3.62(m,8H),7.36-7.28(m,3H),4.18(brs,1H),3.65(t,J=6.4Hz,2H),1.98-1.89(m,2H),1.63-1.50(m,4H),1.46-1.38(m,2H),1.36-1.27(m,2H),1.07(s,9H);13CNMR(100MHz,CDCl3)δ135.7,134.2,131.7,129.6,128.8,128.5,127.7,122.3,86.0,85.5,75.0(q,JC-F=25.5Hz),64.0,46.2,33.0,32.6,30.2,27.0,25.7,22.8,19.3;19F NMR(376MHz,CDCl3)δ-76.55;HRMS m/z Calcd.for C33H41F3NO2Si(M+H+):568.2853;Found:568.2859.
实施例20:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4l
与实施例9相比,区别仅在于:采用三氟酮3l取代3a,其余同实施例3。柱层析得到化合物4l(淡黄色油状液体,51.8mg,产率73%)。
4l的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4l的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Pale yellow oil;M.p.32-35℃;[α]D 25=9.6(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ7.45-7.38(m,2H),7.38-7.28(m,3H),5.86-5.73(m,1H),4.98(d,J=16.8Hz,1H),4.92(d,J=10.0Hz,1H),2.01(q,J=7.0,14.0Hz,2H),1.98-1.86(m,2H),1.59-1.46(m,2H),1.40-1.23(m,8H);13C NMR(100MHz,CDCl3)δ139.3,131.8,128.8,128.5,122.3,114.3,33.9,30.4,29.3,29.1,29.0,22.8;19F NMR(376MHz,CDCl3)δ-76.6;HRMS m/z Calcd.forC20H27F3NO(M+H+):354.2039;Found:354.2047.
实施例21:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4m
与实施例9相比,区别仅在于:采用三氟酮3m取代3a,其余同实施例3。柱层析得到化合物4m(黄色油状液体,46.6mg,产率66%)。
4m的dr值是通过1H NMR分析其反应粗产物以及HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其dr值为大于20:1:-:-。
Yellow oil;[α]D 25=33.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.45-7.37(m,2H),7.37-7.28(m,3H),5.07(t,J=7.4Hz,1H),4.13(s,1H),2.09-1.93(m,2H),1.93-1.83(m,2H),1.81-173(m,1H),1.65(s,3H),1.56(s,3H),1.54-1.48(m,1H),1.28-1.17(m,1H),1.04(d,J=6.4Hz,3H);13C NMR(100MHz,CDCl3)δ131.8,131.4,128.8,128.5,126.4(q,JC-F=285.7Hz),124.8,122.4,87.1,85.8,75.5(q,JC-F=25.4Hz),47.15,47.13,39.0,38.9,28.2,25.8,25.6,21.5,17.7;19F NMR(376MHz,CDCl3)δ-77.4;HRMS m/z Calcd.forC20H27F3NO(M+H+):354.2039;Found:354.2039.
实施例22:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4n
与实施例9相比,区别仅在于:采用三氟酮3n取代3a,其余同实施例3。柱层析得到化合物4n(黄色固体,84.2mg,产率64%)。
4n的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1:-:-。
Yellow solid;M.p.85-89℃;[α]D 25=92.1(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ7.43-7.37(m,2H),7.36-7.28(m,3H),5.04(s,1H),4.76-4.63(m,1H),4.17(s,1H),2.03(s,6H),1.93-1.74(m,4H),1.72-1.50(m,8H),1.48-1.31(m,5H),1.31-1.14(m,4H),1.13-0.94(m,3H),0.88(s,3H),0.82(d,J=6.4Hz,3H),0.67(s,3H);13C NMR(100MHz,CDCl3)δ170.7,170.6,131.7,128.9,128.5,126.4(q,JC-F=286.2Hz),122.3,86.8,85.5,76.1,75.0(q,JC-F=24.9Hz),74.3,49.6,47.5,46.1,45.1,41.9,35.8,35.6,34.8,34.5,34.1,32.4,29.7,28.2,27.4,27.0,26.7,26.0,25.7,23.5,23.2,21.6,21.4,17.8,12.5;19FNMR(376MHz,CDCl3)δ-76.7;HRMS m/z Calcd.for C38H53F3NO5(M+H+):660.3870;Found:660.3881.
实施例23:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4o
与实施例9相比,区别仅在于:采用炔丙胺2b取代2a,其余同实施例3。柱层析得到化合物4o(黄色固体,50.3mg,产率63%)。
4o的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4o的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Yellow solid;M.p.69-72℃;[α]D 25=26.5(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.12(d,J=8.8Hz,1H),7.86(d,J=8.0Hz,1H),7.73(d,J=7.2Hz,1H),7.45(t,J=7.6Hz,1H),7.42-7.29(m,5H),7.00(t,J=8.4Hz,2H),4.25(s,1H),3.49-3.35(m,1H),3.35-3.19(m,1H),2.43-2.27(m,2H);13C NMR(100MHz,CDCl3)δ162.9(q,JC-F=248.8Hz),138.0,134.1,133.8(q,JC-F=8.4Hz),131.8,129.0,127.1,126.33(q,JC-F=285.4Hz),126.23(q,JC-F=14.9Hz),125.73(q,JC-F=11.5Hz),123.7,118.2(q,JC-F=3.7Hz),115.8(q,JC-F=22.0Hz),86.5,84.9,75.1(q,JC-F=25.6Hz),46.3,34.3,26.7;19F NMR(376MHz,CDCl3)δ-76.4,-109.9;HRMS m/z Calcd.for C23H20F4NO(M+H+):402.1476;Found:402.1472.
实施例24:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4p
与实施例9相比,区别仅在于:采用炔丙胺2c取代2a,其余同实施例3。柱层析得到化合物4p(黄色固体,62.4mg,产率71%)。
4p的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4p的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为99%。
Yellow solid;M.p.68-72℃;[α]D 25=15.9(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.10(d,J=8.4Hz,1H),7.97(d,J=7.6Hz,2H),7.85(d,J=8.4Hz,1H),7.72(d,J=7.2Hz,1H),7.43(q,J=8.2Hz,3H),7.39-7.29(m,3H),4.27(s,1H),3.93(s,3H),3.47-3.35(m,1H),3.34-3.21(m,1H),2.41-2.27(m,2H);13C NMR(100MHz,CDCl3)δ166.5,138.0,134.1,131.8,130.2,129.7,129.0,127.1,126.8,126.31,126.29(q,JC-F=285.4Hz),126.2,125.8,125.7,123.7,89.8,85.2,75.2(q,JC-F=25.6Hz),52.4,46.4,34.3,26.7;19FNMR(376MHz,CDCl3)δ-76.4;HRMS m/z Calcd.for C25H23F3NO3(M+H+):442.1625;Found:442.1626.
实施例25:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4q
与实施例9相比,区别仅在于:采用炔丙胺2d取代2a,其余同实施例3。柱层析得到化合物4q(黄色固体,65.5mg,产率81%)。
4q的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4q的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.57-61℃;[α]D 25=26.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.14(d,J=8.4Hz,1H),7.85(d,J=8.4Hz,1H),7.76-7.70(m,1H),7.45(t,J=7.6Hz,1H),7.42-7.33(m,3H),7.30(d,J=8.0Hz,2H),7.13(d,J=7.6Hz,2H),4.26(s,1H),3.47-3.26(m,2H),2.37(s,3H).13C NMR(100MHz,CDCl3)δ139.1,138.1,134.1,131.9,131.8,129.3,128.9,127.0,126.4(q,JC-F=285.3Hz),126.3,126.2,125.8,125.6,123.8,119.1,86.2,86.1,75.2(q,JC-F=25.7Hz),46.3,34.4,26.7,21.6;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/z Calcd.for C24H23F3NO(M+H+):398.1726;Found:398.1727.
实施例26:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4r
与实施例9相比,区别仅在于:采用炔丙胺2e取代2a,其余同实施例3。柱层析得到化合物4r(黄色油状液体,59.0mg,产率71%)。
4r的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4r的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Yellow oil;[α]D 25=21.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.15(d,J=8.4Hz,1H),7.85(d,J=8.4Hz,1H),7.75-7.71(m,1H),7.45(t,J=7.6Hz,1H),7.42-7.32(m,5H),6.84(d,J=8.4Hz,2H),4.26(s,1H),3.82(s,3H),3.46-3.24(m,2H),2.36(t,J=8.8Hz,1H);13C NMR(100MHz,CDCl3)δ160.0,138.1,134.0,133.3,131.8,128.9,127.0,126.4(q,JC-F=285.5Hz),126.3,126.2,125.8,125.6,123.8,114.2,114.1,85.9,85.4,75.1(q,JC-F=25.6Hz),55.4,46.3,34.4,26.7;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/zCalcd.for C24H23F3NO2(M+H+):414.1675;Found:414.1676.
实施例27:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4s
与实施例9相比,区别仅在于:采用炔丙胺2f取代2a,其余同实施例3。柱层析得到化合物4s(黄色固体,60.8mg,产率73%)。
4s的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4s的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.63-68℃;[α]D 25=27.6(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.13(d,J=8.4Hz,1H),7.87(d,J=8.4Hz,1H),7.74(d,J=7.6Hz,1H),7.47(t,J=7.6Hz,1H),7.44-7.36(m,4H),7.34(d,J=7.2Hz,1H),7.29-7.21(m,2H),4.25(s,1H),3.42(td,J=12.8,5.8Hz,1H),3.30(td,J=12.8,5.8Hz,1H),2.44-2.27(m,1H);13C NMR(100MHz,CDCl3)δ144.0,134.4,131.8,130.0,129.0,128.7,128.6,126.7,126.4,126.3(q,JC-F=285.5Hz),122.1,86.5,86.0,74.7(q,JC-F=25.8Hz),46.2,34.8,29.2;19F NMR(376MHz,CDCl3)δ-76.3;HRMS m/z Calcd.for C23H20ClF3NO(M+H+):418.1180;Found:418.1179.
实施例28:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4t
与实施例9相比,区别仅在于:采用炔丙胺2g取代2a,其余同实施例3。柱层析得到化合物4t(黄色固体,64.5mg,产率70%)。
4t的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4t的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为94%。
Yellow solid;M.p.49-51℃;[α]D 25=15.6(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ8.13(d,J=8.4Hz,1H),7.85(d,J=8.4Hz,1H),7.73(t,J=5.0Hz,1H),7.56(d,J=8.0Hz,1H),7.45(t,J=7.6Hz,1H),7.42-7.34(m,4H),7.24(d,J=7.6Hz,1H),7.18(t,J=7.6Hz,1H),4.28(s,1H),3.43(td,J=13.0,4.6Hz,1H),3.32(td,J=13.2,5.0Hz,1H),2.46(td,J=13.4,5.0Hz,1H),2.37(td,J=13.6,4.6Hz,1H);13C NMR(100MHz,CDCl3)δ138.1,134.0,133.7,132.6,131.8,130.0,128.9,127.2,127.0,126.32(q,JC-F=285.4Hz),126.29,126.1,125.8,125.6,124.3,123.9,91.4,84.6,75.2(q,JC-F=26.0Hz),46.6,34.4,26.6;19F NMR(376MHz,CDCl3)δ-76.3;HRMS m/z Calcd.for C23H20BrF3NO(M+H+):462.0675;Found:462.0673.
实施例29:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4u
与实施例9相比,区别仅在于:采用炔丙胺2h取代2a,其余同实施例3。柱层析得到化合物4u(淡黄色固体,59.1mg,产率68%)。
4u的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4u的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为93%。
Pale yellow solid;M.p.115-118℃;[α]D 25=24.1(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ8.21(d,J=8.0Hz,1H),8.13(d,J=8.4Hz,1H),7.86(d,J=8.4Hz,2H),7.83(d,J=8.4Hz,1H),7.71(d,J=7.2Hz,1H),7.65(d,J=6.8Hz,1H),7.52(t,J=7.6Hz,1H),7.46-7.33(m,5H),7.20(t,J=7.6Hz,1H),4.41(s,1H),3.47(td,J=12.8,5.4Hz,1H),3.37(td,J=12.8,5.8Hz,1H),2.47(pd,J=12.8,5.2Hz,2H);13C NMR(100MHz,CDCl3)δ138.0,134.0,133.4,133.2,131.8,131.0,129.4,128.9,128.5,127.2,127.0,126.7,126.4(q,JC-F=285.4Hz),126.3,126.2,125.9,125.8,125.6,125.2,123.7,119.8,91.6,84.2,75.3(q,JC-F=25.8Hz),46.6,34.5,26.7;19F NMR(376MHz,CDCl3)δ-76.3;HRMS m/zCalcd.for C27H23F3NO(M+H+):434.1726;Found:434.1726.
实施例30:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4v
与实施例9相比,区别仅在于:采用炔丙胺2i取代2a,其余同实施例3。柱层析得到化合物4v(黄色固体,68.5mg,产率82%)。
4v的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4v的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.100-103℃;[α]D 25=40.6(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ8.15(d,J=8.8Hz,H),7.87-7.82(m,2H),7.80(d,J=8.4Hz,1H),7.77-7.69(m,1H),7.48(d,J=5.2Hz,1H),7.43(t,J=7.4Hz,2H),7.40-7.36(m,2H),7.32(t,J=8.4Hz,2H),7.28(d,J=6.0Hz,1H),δ4.29(s,1H),3.49-3.37(m,1H),3.37-3.24(m,1H),2.39(q,J=9.2Hz,2H);13C NMR(100MHz,CDCl3)δ140.2,139.6,138.1,134.0,131.8,128.9,127.7,127.3,127.1,126.4(q,JC-F=285.6Hz),126.3,126.2,125.8,125.7,123.8,123.7,122.6,118.0,86.3,86.2,75.1(q,JC-F=25.8Hz),46.3,34.4,26.7;19F NMR(376MHz,CDCl3)δ-76.4;HRMS m/z Calcd.for C25H21F3NO2(M+H+):424.1519;Found:424.1524.
实施例31:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4w
与实施例9相比,区别仅在于:采用炔丙胺2j取代2a,其余同实施例3。柱层析得到化合物4w(黄色固体,67.0mg,产率76%)。
4w的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4w的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为97%。
Yellow solid;M.p.85-89℃;[α]D 25=48.3(c=0.1,CH3OH);1H NMR(400MHz,CDCl3)δ8.15(d,J=8.4Hz,1H),7.84(d,J=8.4Hz,1H),7.75-7.69(m,1H),7.64(d,J=5.6Hz,2H),7.43(d,J=8.2Hz,2H),7.38(d,J=4.8Hz,2H),7.31(t,J=9.2Hz,2H),6.72(s,1H),4.27(s,1H),3.49-3.37(m,1H),3.36-3.23(m,1H),2.38(t,J=8.8Hz,2H),1.78(brs,2H);13C NMR(100MHz,CDCl3)δ154.9,146.2,138.1,134.0,131.8,128.9,128.1,127.7,127.0,126.4(q,JC-F=285.3Hz),126.3,126.2,125.8,125.6,125.2,123.8,116.6,111.7,106.6,86.2,85.4,75.1(q,JC-F=25.5Hz),46.3,34.4,26.7;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/z Calcd.for C25H21F3NOS(M+H+):440.1290;Found:440.1303.
实施例32:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4x
与实施例9相比,区别仅在于:采用炔丙胺2k取代2a,其余同实施例3。柱层析得到化合物4x(黄色固体,68.1mg,产率80%)。
4x的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4x的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为96%。
Yellow solid;M.p.77-81℃;[α]D 25=21.5(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.13(d,J=8.8Hz,1H),7.85(d,J=8.0Hz,1H),7.73(d,J=7.6Hz,1H),7.46(t,J=7.6Hz,1H),7.43-7.36(m,3H),6.92(d,J=8.0Hz,1H),6.83(s,1H),6.74(d,J=8.0Hz,1H),5.98(s,2H),4.23(s,1H),3.47-3.35(m,1H),3.34-3.24(m,1H),2.41-2.28(m,2H);13C NMR(100MHz,CDCl3)δ148.4,147.6,138.1,134.1,131.8,128.9,127.1,126.6,126.4(q,JC-F=285.4Hz),126.3,126.2,125.8,125.7,123.8,115.4,111.7,108.6,101.5,85.8,85.2,75.2(q,JC-F=25.6Hz),46.3,34.3,26.7;19F NMR(376MHz,CDCl3)δ-76.4;HRMS m/z Calcd.forC24H21F3NO3(M+H+):428.1468;Found:428.1468.
实施例33:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4y
依次将手性吡哆醛催化剂(S)-1(7.6mg,0.02mmol)、K2CO3(41.5mg,0.30mmol)加入到2mL反应瓶中,注入CHCl3(0.3mL),再依次注入炔丙胺2l(47.7mg,0.3mmol)、三氟酮3a(50.4mg,0.20mmol)、H2O(20μL),加入搅拌子,盖上塞子,40℃下搅拌36小时。之后加入一水合肼溶液(20μL,80wt%in H2O)搅拌30min淬灭反应,旋去溶剂,柱层析得到化合物4y(淡黄色固体,52.6mg,产率64%)。
4y的dr值是通过1H NMR分析其反应粗产物得到,其dr值为13:1;4y的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为89%。
Pale yellow solid;M.p.65-69℃;[α]D 25=9.1(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ8.14(d,J=8.0Hz,1H),7.89(d,J=8.4Hz 1H),7.76(d,J=8.0Hz,1H),7.52(q,J=7.6Hz,2H),7.43(t,J=7.8Hz,1H),7.35(d,J=7.2Hz,1H),7.21(t,J=7.2Hz,2H),7.18-7.10(m,3H),3.99(s,1H),3.35(td,J=12.8,5.4Hz,1H),3.24(td,J=12.8,5.4Hz,1H),2.77(t,J=7.6Hz,2H),2.51(t,J=7.6Hz,2H),2.22(qd,J=13.2,5.2Hz,2H);13C NMR(100MHz,CDCl3)δ140.3,138.3,134.1,131.9,129.0,128.5,127.0,126.5,126.4(q,JC-F=285.5Hz),126.2,126.1,125.8,125.7,123.8,85.9,78.7,74.9(q,JC-F=25.6Hz),46.0,34.8,34.1,26.6,20.9;19F NMR(376MHz,CDCl3)δ-76.1;HRMS m/z Calcd.for C25H25F3NO(M+H+):412.1883;Found:412.1881.
实施例34:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4z
与实施例33相比,区别仅在于:采用炔丙胺3j取代3a,其余同实施例27。柱层析得到化合物4z(淡黄色固体,52.2mg,产率61%)。
4z的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于20:1;4z的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为94%。
Pale yellow solid;M.p.47-52℃;[α]D 25=2.5(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.31(t,J=7.4Hz,2H),7.23(t,J=8.0Hz,3H),3.89(s,1H),2.83(t,J=7.6Hz,2H),2.52(t,J=7.6Hz,2H),1.84-1.71(m,2H),1.46-1.38(m,2H),1.33-1.20(m,18H),0.90(t,J=6.8Hz,H);13C NMR(100MHz,CDCl3)δ140.5,128.5,126.5,126.4(q,JC-F=285.7Hz),85.3,78.7,74.8(q,JC-F=25.3Hz),45.9,34.9,33.0,32.1,30.5,29.83,29.80,29.7,29.6,29.5,22.8,22.7,20.9,14.2;19F NMR(376MHz,CDCl3)δ-76.4;HRMS m/z Calcd.forC25H39F3NO(M+H+):426.2978;Found:426.2978.
实施例35:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4aa
与实施例34相比,区别仅在于:采用炔丙胺2m取代2l,其余同实施例28。柱层析得到化合物4aa(黄色油状液体,69.3mg,产率71%)。
4aa的dr值是通过1H NMR分析其反应粗产物得到,其dr值为大于13:1;4aa的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为92%。
Yellow oil;[α]D 25=2.6(c=0.1,CHCl3);1H NMR(400MHz,CHCl3)δ3.92(s,1H),2.18(t,J=7.2Hz,2H),1.94-1.72(m,2H),1.54-1.40(m,4H),1.38-1.20(m,36H),0.88(t,J=6.6Hz,6H);13C NMR(101MHz,CDCl3)δ126.5(q,JC-F=285.7Hz),86.2,77.8,74.8(q,JC-F=25.2Hz),45.87,45.85,33.2,32.1,30.6,29.9,29.84,29.81,29.78,29.71,29.6,29.5,29.3,29.0,28.7,22.84,22.81,18.8,14.2;19F NMR(376MHz,CHCl3)δ-76.5;HRMS m/zCalcd.for C29H55F3NO(M+H+):490.4230;Found:490.4235.
实施例36:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4ab
与实施例34相比,区别仅在于:采用炔丙胺2n取代2l,其余同实施例28。柱层析得到化合物4ab(黄色油状液体,50.0mg,产率54%)。
4ab的dr值是通过1H NMR分析其反应粗产物得到,其dr值为19:1;4ab的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为90%。
Yellow oil;[α]D 25=5.5(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ5.87-5.73(m,1H),4.99(d,J=17.2Hz,1H),4.93(d,J=10.0Hz,1H),3.91(s,1H),2.18(t,J=7.2Hz,2H),2.04(q,J=7.2Hz,2H),1.90-1.76(m,2H),1.56-1.42(m,4H),1.41-1.34(m,4H),1.34-1.13(m,24H),0.88(t,J=6.6Hz,3H);13C NMR(100MHz,CDCl3)δ139.3,126.5(q,JC-F=285.7Hz),114.3,86.2,77.8,74.8(q,JC-F=25.2Hz),46.9,33.9,33.2,32.1,30.5,29.84,29.82,29.81,29.80,29.6,29.5,29.24,29.22,29.1,29.0,28.7,22.83,22.80,18.8,14.2;19F NMR(376MHz,CDCl3)δ-76.5;HRMS m/z Calcd.for C27H49F3NO(M+H+):460.3761;Found:460.3763.
实施例37:手性吡哆醛类催化剂(S)-1g催化合成β-胺基-α-三氟甲基醇4ac
与实施例34相比,区别仅在于:采用炔丙胺2o取代2l,其余同实施例28。柱层析得到化合物4ac(淡黄色油状液体,61.4mg,产率64%)。
4ac的dr值是通过1H NMR分析其反应粗产物得到,其dr值为14:1;4ac的ee值是通过HPLC分析其与N,N’-硫羰基二咪唑衍生化后的产物得到,其ee值为92%。
Pale yellow oil;[α]D 25=3.4(c=0.1,CHCl3);1H NMR(400MHz,CDCl3)δ7.37-7.32(m,4H),7.31-7.27(m,1H),4.51(s,2H),3.91(s,1H),3.49(t,J=6.4Hz,2H),2.24(t,J=6.8Hz,2H),1.89-1.78(m,2H),1.75-1.68(m,2H),1.65-1.58(m,2H),1.51-1.40(m,2H),1.32-1.24(m,17H),0.89(t,J=6.6Hz,1H).13C NMR(100MHz,CDCl3)δ138.7,128.5,127.69,127.66,126.5(q,JC-F=285.8Hz),85.8,78.1,74.8(q,JC-F=25.2Hz),73.0,69.8,45.8,33.1,32.0,30.5,29.81,29.79,29.7,29.6,29.5,29.0,25.4,22.81,22.77,18.6,14.2.19FNMR(376MHz,CDCl3)δ-76.4;HRMS m/z Calcd.for C28H45F3NO2(M+H+):484.3397;Found:484.3405.
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (10)
2.根据权利要求1所述的一种吡哆醛催化剂,其特征在于,R1为羟甲基、甲基、乙基、正丙基、异丙基、正丁基、环戊基、环己基、环庚基、苯基、苄基、(1-苯基)乙基、1-萘基、2-萘基或卤素中的一种;
R2、R3分别为氢、甲基、乙基、正丙基、异丙基、正丁基、叔丁基、环戊基、环己基、环庚基、苯基、苄基、2-联苯基、3-联苯基、4-联苯基、2,6-二联苯基、3,5-二联苯基、1-萘基或2-萘基中的一种。
4.根据权利要求3所述的一种吡哆醛催化剂的制备方法,其特征在于,所述的缩合反应中,手性酸化合物与氨基醇化合物的摩尔比为1:(1-5),反应温度为0-100℃,反应时间为1-48h。
5.根据权利要求4所述的一种吡哆醛催化剂的制备方法,其特征在于,所述的缩合剂包括EDCl、DCC、DIC、HATU、HBTU、HCTU、TBTU、TSTU、TNTU、HOAt、HOBt中的至少一种,手性酸化合物与缩合剂的摩尔比为1:(1-10);
所述的碱包括氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾、氢化钙、氟化钾、三乙胺、二异丙胺、二异丙基乙基胺、四甲基乙二胺、N,N-二甲基苯胺、N,N-二乙基苯胺、1,4-二氮杂二环辛烷、二氮杂二环十二烷、正丁基锂、1,4-二甲基哌嗪、1-甲基哌啶、1-甲基吡咯、喹啉或吡啶中的至少一种,手性酸化合物与碱的摩尔比为1:(1-10)。
6.根据权利要求3所述的一种吡哆醛催化剂的制备方法,其特征在于,水解过程中,式7所示的化合物与酸的摩尔比为1:(1-50),反应温度为0-100℃,反应时间为1-48h。
7.根据权利要求6所述的一种吡哆醛催化剂的制备方法,其特征在于,所述的酸包括硫酸、盐酸、磷酸、氢溴酸、氢碘酸、醋酸、三氟乙酸、三氯乙酸、苯磺酸、对甲苯磺酸、甲磺酸或三氟甲磺酸中的至少一种。
8.如权利要求1或2所述的一种手性吡哆醛催化剂的应用,其特征在于,所述的吡哆醛催化剂用于三氟甲基酮的不对称加成反应,包括:
将式2所示的炔丙胺、式3所示的三氟甲基酮混合,并在吡哆醛催化剂与碱的作用下进行不对称加成反应,得到式(3R,4S)-4所示的化合物或式(3S,4S)-4所示的化合物;
式中,R4、R5分别为氢、下述基团或者含有取代基的下述基团:C1~C24的烃基、C3~C30的环烷基或芳基、C1~C24的羰基、C1~C24的磺酰基或磷酰基;
所述的取代基包括卤素、C1~C8的烃基、C3~C12的环烷基或芳基、C1~C8的羰基、C1~C8的磺酰基或磷酰基、C1~C8的烷氧基或胺基中的至少一种;
其中,所述的羰基为醛基、酮羰基、酯羰基、羧基或酰胺基。
9.根据权利要求8所述的一种吡哆醛催化剂的应用,其特征在于,所述的不对称加成反应中,式2所示的炔丙胺、式3所示的三氟甲基酮、吡哆醛催化剂的摩尔比为(0.5-5):1:(0.01-0.5),反应温度为-10℃至100℃,反应时间为1-72h。
10.根据权利要求9所述的一种吡哆醛催化剂的应用,其特征在于,所述的碱包括氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、氢化钠、氢化钾、氢化钙、氟化钾、三乙胺、二异丙胺、二异丙基乙基胺、四甲基乙二胺、N,N-二甲基苯胺、N,N-二乙基苯胺、1,4-二氮杂二环辛烷、二氮杂二环十二烷、正丁基锂、1,4-二甲基哌嗪、1-甲基哌啶、1-甲基吡咯、喹啉或吡啶中的至少一种;炔丙胺与碱的摩尔比为1:(1-20)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210459627.8A CN114853667B (zh) | 2022-04-27 | 2022-04-27 | 一种手性吡哆醛催化剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210459627.8A CN114853667B (zh) | 2022-04-27 | 2022-04-27 | 一种手性吡哆醛催化剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114853667A true CN114853667A (zh) | 2022-08-05 |
CN114853667B CN114853667B (zh) | 2023-10-27 |
Family
ID=82632953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210459627.8A Active CN114853667B (zh) | 2022-04-27 | 2022-04-27 | 一种手性吡哆醛催化剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114853667B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106111190A (zh) * | 2016-06-20 | 2016-11-16 | 上海师范大学 | 一种手性联芳骨架吡哆胺类催化剂及其合成方法与应用 |
US20170275240A1 (en) * | 2014-09-26 | 2017-09-28 | Shanghai Jiaotong University | METHOD FOR PREPARING CHIRAL gamma-SECONDARY AMINO ALCOHOL |
CN108947894A (zh) * | 2018-06-28 | 2018-12-07 | 上海师范大学 | 新型联芳结构手性n-甲基吡哆醛催化剂及其合成和应用 |
CN111269132A (zh) * | 2020-01-21 | 2020-06-12 | 上海师范大学 | 一种制备手性β-三氟甲基-β-羟基-α-氨基酸及其衍生物的方法 |
WO2021083018A1 (zh) * | 2019-10-30 | 2021-05-06 | 浙江九洲药业股份有限公司 | 吡啶环上3-位取代手性螺环胺基膦配体制备方法及其应用 |
-
2022
- 2022-04-27 CN CN202210459627.8A patent/CN114853667B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170275240A1 (en) * | 2014-09-26 | 2017-09-28 | Shanghai Jiaotong University | METHOD FOR PREPARING CHIRAL gamma-SECONDARY AMINO ALCOHOL |
CN106111190A (zh) * | 2016-06-20 | 2016-11-16 | 上海师范大学 | 一种手性联芳骨架吡哆胺类催化剂及其合成方法与应用 |
CN108947894A (zh) * | 2018-06-28 | 2018-12-07 | 上海师范大学 | 新型联芳结构手性n-甲基吡哆醛催化剂及其合成和应用 |
WO2021083018A1 (zh) * | 2019-10-30 | 2021-05-06 | 浙江九洲药业股份有限公司 | 吡啶环上3-位取代手性螺环胺基膦配体制备方法及其应用 |
CN111269132A (zh) * | 2020-01-21 | 2020-06-12 | 上海师范大学 | 一种制备手性β-三氟甲基-β-羟基-α-氨基酸及其衍生物的方法 |
Non-Patent Citations (4)
Title |
---|
AOLIN CHENG等: "Efficient Asymmetric Biomimetic Aldol Reaction of Glycinates and Trifluoromethyl Ketones by Carbonyl Catalysis", 《ANGEW. CHEM. INT. ED.》, pages 20166 - 20172 * |
JIANFENG CHEN等: "Carbonyl catalysis enables a biomimetic asymmetric Mannich reaction", 《SCIENCE》, pages 1438 - 1442 * |
PENGWEI JI等: "Direct Asymmetric α-C-H Addition of N-unprotected Propargylic Amines to Trifluoromethyl Ketones by Carbonyl Catalysis", 《ANGEW. CHEM. INT. ED.》, pages 1 - 6 * |
陈剑锋等: "仿生不对称转氨化合成手性α,ω -二氨基酸", 《合成化学》, vol. 27, no. 9, pages 680 - 688 * |
Also Published As
Publication number | Publication date |
---|---|
CN114853667B (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108947894B (zh) | 联芳结构手性n-甲基吡哆醛催化剂及其合成和应用 | |
CN111269132B (zh) | 一种制备手性β-三氟甲基-β-羟基-α-氨基酸及其衍生物的方法 | |
Kawano et al. | Lewis base-catalyzed trifluoromethylation of aldimines with (trifluoromethyl) trimethylsilane | |
CN114920775B (zh) | 一种轴手性双吲哚催化剂及其合成方法与应用 | |
CN114733566B (zh) | 一种基于binol骨架的手性超强碳酸催化剂及其制备方法与应用 | |
CN114853667A (zh) | 一种手性吡哆醛催化剂及其制备方法与应用 | |
CN114409592B (zh) | 一种c3位带有侧链的联芳结构手性吡哆醛催化剂及其制备方法与应用 | |
CN115073251B (zh) | 一种不对称催化合成尼古丁的方法 | |
CN115108937B (zh) | 含三级立体中心的α-叠氮酮的合成方法 | |
CN113999131B (zh) | 可见光促进镍催化烷基c-h键胺化制备酰胺衍生物的方法 | |
CN113461589B (zh) | 一种手性2,3-二取代吲哚胺类化合物及其制备方法 | |
CN113444125B (zh) | 亚磷酰胺配体及其制备方法和在不对称羰基化反应中的应用 | |
CN111320651A (zh) | 手性氨基-吡啶-膦三齿配体、锰络合物、其制备方法和应用 | |
CN114920702A (zh) | 不对称共轭加成合成光学活性咪唑酮类化合物的方法 | |
CN109666043B (zh) | 一类吡啶骨架的手性单膦配体CF-Phos及其制备方法和应用 | |
CN109748883B (zh) | 手性β-氨基衍生物的制备方法 | |
CN110590781B (zh) | 不对称烯丙基胺化反应合成手性五元碳环嘌呤核苷的方法 | |
CN112300214B (zh) | 钯复合物、其制备方法、轴手性联芳香化合物的制备方法 | |
CN107827890B (zh) | 通过嘌呤、醛和酸酐的动态动力学拆分合成手性嘌呤非环核苷的方法 | |
Yang et al. | Organocatalytic aminocarbonylation of α, β-unsaturated ketones with N, N-dimethyl carbamoylsilane | |
CN112552343A (zh) | 一种轴手性萘-吲哚类膦催化剂及其制备方法与应用 | |
CN115490728B (zh) | 一种烯丙基膦衍生物的合成方法 | |
CN115043775B (zh) | 一种手性吡哆醛催化剂及其制备方法与应用 | |
CN110467556B (zh) | 一种镍催化亚胺离子与苯乙酮的亲核反应方法 | |
CN115057996B (zh) | 4CzIPN型多孔有机聚合物的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |